Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Vertex Pharmaceuticals ( VRTX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.5%. By the end of trading, Vertex Pharmaceuticals fell $1.73 (-2.2%) to $75.99 on heavy volume. Throughout the day, 3,743,438 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2,331,900 shares. The stock ranged in price between $74.61-$79.41 after having opened the day at $75.90 as compared to the previous trading day's close of $77.72. Other companies within the Drugs industry that declined today were: Delcath Systems ( DCTH), down 42.0%, Aoxing Pharmaceutical Company ( AXN), down 16.0%, Sangamo BioSciences ( SGMO), down 10.3% and Arena Pharmaceuticals ( ARNA), down 9.2%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $16.8 billion and is part of the health care sector. Shares are up 83.4% year to date as of the close of trading on Thursday. Currently there are 15 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow.

On the positive front, China Pharma ( CPHI), down 9.3%, Neptune Technologies & Bioressources ( NEPT), down 9.3%, TrovaGene ( TROV), down 8.0% and pSivida ( PSDV), down 7.8% , were all gainers within the drugs industry with Celgene Corporation ( CELG) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing